Cart
Your cart is empty
Find
Single-chain dual GIP / GLP-1 receptor agonist · C20 acyl
Tirzepatide is a synthetic peptide that activates the receptors for two gut hormones, GIP and GLP-1, which are involved in regulating blood sugar and appetite. Researchers use it to study how these two hormone signals work together to influence glucose control, food intake, and body weight in laboratory models.
Launch Sale · Ends Nov 6
Get an email when it restocks
One email the moment it can be ordered — plus sale pricing and new journal entries on Tirzepatide.
Tested lot by lot at ≥99% purity. The Janoshik certificate for your lot is emailed with the order.
Everything Valtrax Research ships is bench material for in-vitro work. None of it is a drug, a supplement, a cosmetic, or a medical device, and none of it is intended for human or animal use, ingestion, or administration. Placing an order is your confirmation that you are a qualified researcher buying for lawful research, under every Canadian law and regulation that applies to you.
One 39-residue chain, two receptors. Tirzepatide is built on a GIP backbone tuned so a single molecule fits both the GIP and the GLP-1 receptor — not two peptides stuck together, but one sequence engineered for dual agonism. A C20 fatty-acid chain anchors it to albumin and stretches the half-life to once-weekly territory.
The two non-coded Aib residues are the structural tell: they block the proteases that would otherwise clear an incretin in minutes. That engineering is why labs treat tirzepatide as the reference case for asking what co-activating both incretin arms does that hitting either one alone does not.
The core question is additivity: does engaging GIP and GLP-1 receptors from one molecule beat engaging GLP-1 alone? Studies dissect the dual-agonist pharmacology, then test it against single-incretin comparators on glucose control and body weight. The SURPASS and SURMOUNT trials supply the head-to-head data the mechanism is judged against.
The interesting variable is the second receptor. GLP-1 agonism is well-mapped; what tirzepatide adds is simultaneous GIP-receptor activation from the same molecule, so research uses it to separate the contribution of each arm and to look for synergy between them in metabolic models.
The trial record is dense and head-to-head. Frías ran it against semaglutide in SURPASS-2, Del Prato against insulin glargine in SURPASS-4, and Jastreboff against placebo for body weight in SURMOUNT-1 — a body of work that benchmarks dual agonism against single-incretin comparators on glycemic and weight endpoints.
Tirzepatide grew out of the observation that GIP, long sidelined as the weaker incretin, might amplify GLP-1’s effect if both were engaged together. Rather than co-formulate two peptides, the design folded both activities into one GIP-derived sequence — a deliberately unimolecular approach to dual agonism.
The acylation and Aib substitutions that followed solved the practical problems, half-life and protease resistance, that any once-weekly incretin has to clear before it can be studied at all.
A structured evidence summary for this item is still being written. The primary literature listed under Molecule is the starting point in the meantime.
Jastreboff, A.M. et al. (2022). Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1).
PubMedFrías, J.P. et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2).
PubMedDel Prato, S. et al. (2021). Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 398(10313):1811–1824.
PubMedJanoshik Analytical measures identity, purity, and net content, lot by lot.
Janoshik Analytical, a laboratory Valtrax does not own, runs the testing — identity by mass spectrometry, purity by RP-HPLC at ≥99%, on the lot you receive.
Same Shelf
